FDA gives emergency-use approval for Abbott's $5, 15-minute COVID-19 test, though not for home use
Abbott Laboratories said Wednesday that the Food and Drug Administration had granted it emergency-use authorization for its quick, inexpensive COVID-19 antigen test, and it plans to ship tens of millions of the tests in September. The test, called the BinaxNOW COVID-19 Ag Card, is about the size of a credit card, will cost $5 each, and returns results in about 15 minutes, Abbott says. It works kind of like a pregnancy test but still involves and nasal swab and needs to be administered by medical professionals, typically in a doctor's office or by a school nurse. It won't be sold directly to consumers for home use.
This isn't the first rapid COVID-19 test given a provisional green light by the FDA. Similar antigen tests are processed in boxlike machines and cost anywhere from $15 to $50, The Wall Street Journal reports. Abbott also makes a rapid-response molecular test used in the White House, though that was shown to be returning frequent false negatives. The newly approved antigen test has been shown to accurately detect positive cases about 97 percent of the time, Abbott said.
The test should help meet a growing demand for cheap, less-accurate COVID-19 tests that some public health officials argue the U.S. needs to return to school and work.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Political cartoons for October 26Cartoons Sunday’s editorial cartoons include Young Republicans group chat, Louvre robbery, and more
-
Why Britain is struggling to stop the ransomware cyberattacksThe Explainer New business models have greatly lowered barriers to entry for criminal hackers
-
Greene’s rebellion: a Maga hardliner turns against TrumpIn the Spotlight The Georgia congresswoman’s independent streak has ‘not gone unnoticed’ by the president
-
Warner Bros. explores sale amid Paramount bidsSpeed Read The media giant, home to HBO and DC Studios, has received interest from multiple buying parties
-
Gold tops $4K per ounce, signaling financial uneaseSpeed Read Investors are worried about President Donald Trump’s trade war
-
Electronic Arts to go private in record $55B dealspeed read The video game giant is behind ‘The Sims’ and ‘Madden NFL’
-
New York court tosses Trump's $500M fraud fineSpeed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in IntelSpeed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to ChinaSpeed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with DisneySpeed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B dealSpeed Read Tesla has signed a deal to get its next-generation chips from Samsung
